SCHEMBL16019491

SCHEMBL16019491

CC(=O)N(C)c1cc(C(C)C)ccn1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.38
SMN1; SMN2 Q16637 5/20 0.38
LMNA P02545 3/20 0.38
BUB1 O43683 1/20 0.35
LIPE Q05469 1/20 0.34
KDM4E B2RXH2 4/20 0.33
BCHE P06276 2/20 0.33
ACHE P22303 2/20 0.33
FSCN1 Q16658 1/20 0.33
POLB P06746 1/20 0.33
HSP90AA1 P07900 1/20 0.33
HSP90AB1 P08238 1/20 0.33
GAA P10253 1/20 0.32
CHRNA7 P36544 1/20 0.32
BCL6 P41182 1/20 0.32
RNASEH1 O60930 1/20 0.32
MDM4 O15151 1/20 0.32
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32
TP53 P04637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20889611 0.85 IDH1 (0.37) ALDH1A1SMN1; SMN2LMNALIPEKDM4E
SCHEMBL568452 0.80 ROCK1 (0.34) ALDH1A1SMN1; SMN2BUB1POLBMAPT
SCHEMBL12181350 0.80 SMN1; SMN2 (0.34) SMN1; SMN2BUB1POLBMAPT
SCHEMBL15070166 0.79 AAK1 (0.39) ALDH1A1SMN1; SMN2LMNAKDM4EBCHE
SCHEMBL12530261 0.78 EED (0.37) ALDH1A1LMNAKDM4EGAACHRNA7
SCHEMBL18133753 0.77 RAB9A (0.48) ALDH1A1SMN1; SMN2BUB1KDM4EFSCN1
SCHEMBL14769918 0.77 SMN1; SMN2 (0.32) SMN1; SMN2BUB1POLBMAPT
SCHEMBL19501405 0.76 HSP90AA1 (0.38) ALDH1A1SMN1; SMN2LMNAKDM4EBCHE
SCHEMBL15341976 0.76 SMN1; SMN2 (0.45) ALDH1A1SMN1; SMN2LMNAKDM4EPOLB
SCHEMBL20890559 0.76 TRPA1 (0.32) ALDH1A1SMN1; SMN2LMNAKDM4EACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230348452-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-11-02 US disclosed
US-20230149414-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-18 US disclosed
US-20230149414-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-18 US disclosed
US-20230138480-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-04 US disclosed
US-10391175-B2 BET bromodomain inhibitors and therapeutic methods using the same THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2019-08-27 US disclosed
US-20170281773-A1 BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2017-10-05 US disclosed
US-20170281773-A1 BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2017-10-05 US disclosed
US-9675697-B2 BET bromodomain inhibitors and therapeutic methods using the same THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2017-06-13 US disclosed
US-9663533-B2 Thieno[3,2-C]pyridin-4(5H)-ones as BET inhibitors GLAXOSMITHKLINE LLC (US) 2017-05-30 US disclosed
US-9663533-B2 Thieno[3,2-C]pyridin-4(5H)-ones as BET inhibitors GLAXOSMITHKLINE LLC (US) 2017-05-30 US disclosed
US-20160297832-A1 THIENO[3,2-C]PYRIDIN-4(5H)-ONES AS BET INHIBITORS GLAXOSMITHKLINE LLC 2016-10-13 US disclosed
US-20140256706-A1 BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2014-09-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230149414-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB ALDH1A1 2571/4885SMN1; SMN2 40/4885LMNA 225/4885
US-20160297832-A1 THIENO[3,2-C]PYRIDIN-4(5H)-ONES AS BET INHIBITORS BRD4, BET1, BRD3 ALDH1A1 2234/4885SMN1; SMN2 2089/4885LMNA 1082/4885
US-20230138480-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB ALDH1A1 2571/4885SMN1; SMN2 40/4885LMNA 225/4885
US-10391175-B2 BET bromodomain inhibitors and therapeutic methods using the same BRD4, BRDT, BRD3 ALDH1A1 4162/4885SMN1; SMN2 3270/4885LMNA 1865/4885
US-20230348452-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, BRCA1 ALDH1A1 2600/4885SMN1; SMN2 49/4885LMNA 145/4885
US-20170281773-A1 BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME BRD4, BRDT, BRD3 ALDH1A1 4162/4885SMN1; SMN2 3270/4885LMNA 1865/4885
US-20140256706-A1 BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME BRD4, BRDT, BRD3 ALDH1A1 4162/4885SMN1; SMN2 3270/4885LMNA 1865/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.